These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 38612471)

  • 21. Strategies to eradicate HIV from infected patients: elimination of latent provirus reservoirs.
    Sadowski I; Hashemi FB
    Cell Mol Life Sci; 2019 Sep; 76(18):3583-3600. PubMed ID: 31129856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural Products as Anti-HIV Agents and Role in HIV-Associated Neurocognitive Disorders (HAND): A Brief Overview.
    Kurapati KR; Atluri VS; Samikkannu T; Garcia G; Nair MP
    Front Microbiol; 2015; 6():1444. PubMed ID: 26793166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combating the HIV reservoirs.
    van Marle G; Church DL; van der Meer F; Gill MJ
    Biotechnol Genet Eng Rev; 2018 Apr; 34(1):76-89. PubMed ID: 29781356
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A lentiviral vector that activates latent human immunodeficiency virus-1 proviruses by the overexpression of tat and that kills the infected cells.
    Macías D; Oya R; Saniger L; Martín F; Luque F
    Hum Gene Ther; 2009 Nov; 20(11):1259-68. PubMed ID: 19604078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single-Cell Profiling of Latently SIV-Infected CD4
    Tokarev A; Machmach K; Creegan M; Kim D; Eller MA; Bolton DL
    Microbiol Spectr; 2022 Jun; 10(3):e0060422. PubMed ID: 35510859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Hurdles to HIV cure. Part 1 : the latent reservoirs].
    Fombellida-Lopez C; Chaslain A; Susin F; Vaira D; Moutschen M; Darcis G
    Rev Med Liege; 2020 Sep; 75(9):573-577. PubMed ID: 32909407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
    Pierson T; McArthur J; Siliciano RF
    Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suppression of Active HIV-1 Infection in CD34
    Latinovic OS; Neal LM; Tagaya Y; Heredia A; Medina-Moreno S; Zapata JC; Reitz M; Bryant J; Redfield RR
    AIDS Res Hum Retroviruses; 2019 Aug; 35(8):718-728. PubMed ID: 31099257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NIH conference. Antiretroviral therapy in AIDS.
    Broder S; Mitsuya H; Yarchoan R; Pavlakis GN
    Ann Intern Med; 1990 Oct; 113(8):604-18. PubMed ID: 1698042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigenetic regulation of HIV-1 persistence and evolving strategies for virus eradication.
    Dhamija N; Rawat P; Mitra D
    Subcell Biochem; 2013; 61():479-505. PubMed ID: 23150264
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current Strategies for Elimination of HIV-1 Latent Reservoirs Using Chemical Compounds Targeting Host and Viral Factors.
    Jean MJ; Fiches G; Hayashi T; Zhu J
    AIDS Res Hum Retroviruses; 2019 Jan; 35(1):1-24. PubMed ID: 30351168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Newly approved integrase inhibitors for clinical treatment of AIDS.
    Gu WG
    Biomed Pharmacother; 2014 Oct; 68(8):917-21. PubMed ID: 25451165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Targeted Mass Spectrometry Assay for Detection of HIV Gag Protein Following Induction of Latent Viral Reservoirs.
    Schlatzer D; Haqqani AA; Li X; Dobrowolski C; Chance MR; Tilton JC
    Anal Chem; 2017 May; 89(10):5325-5332. PubMed ID: 28467046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structural Insights to Human Immunodeficiency Virus (HIV-1) Targets and Their Inhibition.
    Vanangamudi M; Nair PC; Engels SEM; Palaniappan S; Namasivayam V
    Adv Exp Med Biol; 2021; 1322():63-95. PubMed ID: 34258737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On the way to find a cure: Purging latent HIV-1 reservoirs.
    Schwartz C; Bouchat S; Marban C; Gautier V; Van Lint C; Rohr O; Le Douce V
    Biochem Pharmacol; 2017 Dec; 146():10-22. PubMed ID: 28687465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies.
    Demonté D; Quivy V; Colette Y; Van Lint C
    Biochem Pharmacol; 2004 Sep; 68(6):1231-8. PubMed ID: 15313421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An Update on Antiretroviral Therapy.
    Menéndez-Arias L; Martín-Alonso S; Frutos-Beltrán E
    Adv Exp Med Biol; 2021; 1322():31-61. PubMed ID: 34258736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.